Cargando…

Thermal and Structural Characterization of Two Crystalline Polymorphs of Tafamidis Free Acid

Tafamidis, chemical formula C(14)H(7)Cl(2)NO(3), is a drug used to delay disease progression in adults suffering from transthyretin amyloidosis, and is marketed worldwide under different tradenames as a free acid or in the form of its meglumine salt. The free acid (CAS no. 594839-88-0) is reported t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masciocchi, Norberto, Abbinante, Vincenzo Mirco, Zambra, Marco, Barreca, Giuseppe, Zampieri, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656987/ https://www.ncbi.nlm.nih.gov/pubmed/36364244 http://dx.doi.org/10.3390/molecules27217411

Ejemplares similares

Preparation and Solid-State Characterization of Eltrombopag Crystal Phases
por: Abbinante, Vincenzo Mirco, et al.
Publicado: (2020)

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021)

Polyfluorinated Naphthalene-bis-hydrazimide for Solution-Grown n-Type Semiconducting Films
por: Zambra, Marco, et al.
Publicado: (2023)

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers
por: Lockwood, Peter A., et al.
Publicado: (2020)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
por: Waddington Cruz, Márcia, et al.
Publicado: (2015)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

The Tafamidis Drug Development Program: A Translational Triumph
por: Maurer, Mathew S., et al.
Publicado: (2018)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone
por: Laird, Jessica, et al.
Publicado: (2020)

Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’
por: Damy, Thibaud, et al.
Publicado: (2021)

Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal
por: Coelho, Teresa, et al.
Publicado: (2015)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
por: Rozenbaum, Mark H, et al.
Publicado: (2021)

Monitoring Tafamidis, The Most Expensive Cardiac Medication: Are Serum Transthyretin Levels the Answer?
por: Chang, Ian C., et al.
Publicado: (2021)

Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022)

Impact of Thermal Properties on Crystalline Structure, Polymorphism and Morphology of Polymer Matrices in Composites
por: Raimo, Maria
Publicado: (2021)

The Thermal Structural Transition of α-Crystallin Inhibits the Heat Induced Self-Aggregation
por: Maulucci, Giuseppe, et al.
Publicado: (2011)

Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story
por: Burton, Arianna, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

A Case of Infiltrative Cardiomyopathy With Refractory Pericardial Effusion Successfully Treated With Empiric Tafamidis
por: Chakraborty, Shudipan, et al.
Publicado: (2023)

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
por: Wang, Jie, et al.
Publicado: (2023)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
por: Takashio, Seiji, et al.
Publicado: (2023)

Crystalline Gaq(3)Nanostructures: Preparation, Thermal Property and Spectroscopy Characterization
por: Yu, Ya-Wen, et al.
Publicado: (2009)

The Thermal Structural Transition of Alpha-Crystallin Modulates Subunit Interactions and Increases Protein Solubility
por: Maulucci, Giuseppe, et al.
Publicado: (2012)

Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area
por: Cortese, Andrea, et al.
Publicado: (2015)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy
por: Shintani, Yasuhiro, et al.
Publicado: (2018)

Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
por: Vong, Camille, et al.
Publicado: (2021)

Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias
por: Isotani, Yoshitaka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ta6gbvc5hd6m0d7780rhvruhg